The estimated Net Worth of Lee Kalowski is at least 1.63 百万$ dollars as of 3 April 2023. Mr Kalowski owns over 376 units of Bicycle Therapeutics plc stock worth over 817,131$ and over the last 5 years he sold BCYC stock worth over 60,681$. In addition, he makes 756,131$ as Pres & CFO at Bicycle Therapeutics plc.
Mr has made over 11 trades of the Bicycle Therapeutics plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 376 units of BCYC stock worth 7,937$ on 3 April 2023.
The largest trade he's ever made was exercising 26,970 units of Bicycle Therapeutics plc stock on 23 November 2020 worth over 42,073$. On average, Mr trades about 6,713 units every 57 days since 2019. As of 3 April 2023 he still owns at least 30,309 units of Bicycle Therapeutics plc stock.
You can see the complete history of Mr Kalowski stock trades at the bottom of the page.
Lee H. Kalowski is the Pres & CFO at Bicycle Therapeutics plc.
As the Pres & CFO of Bicycle Therapeutics plc, the total compensation of Mr Kalowski at Bicycle Therapeutics plc is 756,131$. There are 3 executives at Bicycle Therapeutics plc getting paid more, with Dr. Kevin Lee M.B.A., Ph.D. having the highest compensation of 1,156,784$.
Mr Kalowski is 39, he's been the Pres & CFO of Bicycle Therapeutics plc since . There are 11 older and no younger executives at Bicycle Therapeutics plc. The oldest executive at Bicycle Therapeutics plc is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, 70, who is the Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board.
Lee's mailing address filed with the SEC is C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS.
Over the last 5 years, insiders at Bicycle Therapeutics plc have traded over 10,024,476$ worth of Bicycle Therapeutics plc stock and bought 3,275,775 units worth 45,860,850$ . The most active insiders traders include Plc Gsk、Bros. Advisors Lp667, L.P.B...、Bioventures Ltd Novartis Ag.... On average, Bicycle Therapeutics plc executives and independent directors trade stock every 19 days with the average trade being worth of 1,155,236$. The most recent stock trade was executed by Michael Charles Ferguson Ha... on 3 July 2024, trading 246 units of BCYC stock currently worth 4,831$.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc executives and other stock owners filed with the SEC include: